Intrexon | XON - Sales Revenues


Intrexon reported $717K in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Agenus USD 34.2M 3.97M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 9.9B 340M Dec/2025
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Intrexon USD 717K 511K Jun/2024
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
MannKind USD 111.96M 29.83M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Thermo Fisher Scientific USD 12.21B 1.09B Dec/2025
Veracyte USD 140.6M 8.7M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025